Current Problems in Cancer最新文献

{"title":"Blood-based multi-cancer detection: A state-of-the-art update","authors":"Maria Farooq ,&nbsp;Elyse Leevan ,&nbsp;Jibran Ahmed ,&nbsp;Brian Ko ,&nbsp;Sarah Shin ,&nbsp;Andre De Souza ,&nbsp;Naoko Takebe","doi":"10.1016/j.currproblcancer.2023.101059","DOIUrl":"10.1016/j.currproblcancer.2023.101059","url":null,"abstract":"<div><p>The early detection of cancer<span> is a key goal of the National Cancer Plan formally released by the National Institutes of Health's (NIH) National Cancer Institute (NCI) in April 2023. To support this effort, many laboratories and vendors are developing multi-cancer detection (MCD) assays that interrogate blood and other bodily fluids for cancer-related biomarkers, most commonly circulating tumor DNA<span> (ctDNA). While this approach holds promise for non-invasively detecting early signals of multiple different cancers and potentially reducing cancer-related mortality, there is a dearth of prospective clinical data to inform the deployment of MCD assays for cancer screening in the general adult population. In this review we highlight differing technologies that underpin various MCD assays in clinical development, the importance of achieving adequate performance specifications for MCD assays, ongoing clinical studies investigating the utility of MCD assays in cancer screening and detection, and efforts by the NCI's Division of Cancer Prevention (DCP) to establish a network infrastructure that has the capacity to comprehensively address the scientific and logistical challenges of evaluating blood-based MCD approaches and other cancer screening tools.</span></span></p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"48 ","pages":"Article 101059"},"PeriodicalIF":2.6,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139092247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel model to predict the risk of hematological toxicity in lung adenocarcinoma patients with pemetrexed plus platinum chemotherapy based on real-world data","authors":"Wei-Jing Gong ,&nbsp;Peng Cao ,&nbsp;Yi-Fei Huang ,&nbsp;Ya-Ni Liu ,&nbsp;Yu Yang ,&nbsp;Rui Zhang ,&nbsp;Qiang Li ,&nbsp;San-Lan Wu ,&nbsp;Yu Zhang","doi":"10.1016/j.currproblcancer.2023.101058","DOIUrl":"https://doi.org/10.1016/j.currproblcancer.2023.101058","url":null,"abstract":"<div><h3>Background</h3><p>Pemetrexed<span> plus platinum chemotherapy is the first-line treatment<span> option for lung adenocarcinoma. However, hematological toxicity is major dose-limiting and even life-threatening. The ability to anticipate hematological toxicity is of great value for identifying potential chemotherapy beneficiaries with minimal toxicity and optimizing treatment. The study aimed to develop and validate a prediction model for hematologic toxicity based on real-world data.</span></span></p></div><div><h3>Methods</h3><p><span>Data from 1754 lung adenocarcinoma patients with pemetrexed plus platinum chemotherapy regimen as first-line therapy were used to establish and calibrate a risk model for hematological toxicity using multivariate and stepwise </span>logistic regression analysis based on real-world data. The predictive performance of the model was tested in a validation cohort of 753 patients. An area under the curve (AUC) of the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis were used to assess the prediction model.</p></div><div><h3>Results</h3><p>5 independent factors (platinum, pre-use vitamin B12, cycle of chemotherapy before hematological toxicity, Hb before first chemotherapy, and PLT before first chemotherapy) identified from multivariate and stepwise logistic regression analysis were included in the prediction model. The hematological toxicity prediction model achieved a sensitivity of 0.840 and a specificity of 0.822. The model showed good discrimination in both cohorts (an AUC of 0.904 and 0.902 for the derivation and validation cohort ROC) at the cut-off value of 0.591. The calibration curve showed good agreement between the actual observations and the predicted results.</p></div><div><h3>Conclusion</h3><p>We developed a prediction model for hematologic toxicity with good discrimination and calibration capability in lung adenocarcinoma patients receiving a pemetrexed plus platinum chemotherapy regimen based on real-world data.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"48 ","pages":"Article 101058"},"PeriodicalIF":2.6,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138633728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controversies in the treatment of early-stage oral squamous cell carcinoma","authors":"Leonardo Ferrari ,&nbsp;Paolo Cariati ,&nbsp;Imanol Zubiate ,&nbsp;Ángel Martínez-Sahuquillo Rico ,&nbsp;Susana Arroyo Rodriguez ,&nbsp;Rosa Maria Pulgar Encinas ,&nbsp;Silvano Ferrari ,&nbsp;Ildefonso Martínez Lara","doi":"10.1016/j.currproblcancer.2023.101056","DOIUrl":"https://doi.org/10.1016/j.currproblcancer.2023.101056","url":null,"abstract":"<div><p><span><span>The treatment of early-stage </span>oral squamous cell carcinoma (OSCC) is still a controversial issue. Thanks to the 8</span>^th<span><span> edition of TNM by AJCC there is a better distinction between the stages of OSCC. However, Stages I and II still share the same treatment protocol, even if the prognosis is radically different. A retrospective study has been conducted including 70 previously untreated patients with Stage I or II OSCC, treated with tumorectomy and selective neck dissection<span>. The study focuses on the link between pT1/2 and various other factors, particularly histological grading, vascular and perineural invasion<span>, local and cervical recurrence, surgical margins and overall survival. These data reveal significant differences between pT1 and pT2 in histological grade, perineural invasion, cervical recurrence, surgical margins, and overall survival, emphasizing the necessity of different treatment protocols for T1 and T2 OSCC. Distinct strategies should be proposed to treat Stage I and II OSCC, with Stage II patients possibly benefitting from more aggressive treatments: following these data, a wait-and-see strategy should only be considered in Stage I, while certain treatments at the cervical level — such as prophylactic neck dissection and </span></span></span>sentinel node biopsy — should always be considered for Stage II tumors.</span></p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"48 ","pages":"Article 101056"},"PeriodicalIF":2.6,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138633729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnostic value of serum lncRNA CATG00000112921.1 as a marker of multiple myeloma","authors":"Jing Gao ,&nbsp;Jing Qu ,&nbsp;Bin Xiao ,&nbsp;Qiyuan Huang ,&nbsp;Chuiyu Zhu ,&nbsp;Zichang Dai ,&nbsp;Kunhe Wu ,&nbsp;Linhai Li ,&nbsp;Tao Zeng","doi":"10.1016/j.currproblcancer.2023.101057","DOIUrl":"https://doi.org/10.1016/j.currproblcancer.2023.101057","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Multiple myeloma&lt;span&gt; (MM) is a malignant plasma cell disease. At present, numerous studies have shown that lncRNA&lt;span&gt; plays a very important role in the occurrence, development and even drug resistance of multiple myeloma. It may become a potential diagnostic and prognostic marker of multiple myeloma and provide new ideas for targeted therapy. Based on the above research background, this study used gene chip technology to screen out the differentially expressed lncRNA in the serum of MM patients and healthy people, and verified more clinical serum samples to screen out the lncRNA with the largest difference as a biomarker for further research.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Method&lt;/h3&gt;&lt;p&gt;In this research, the data of hospitalized patients diagnosed with MM and healthy people in the Affiliated Hospital of Guangdong Medical University were retrospectively collected. The lncRNA expression profile of serum samples from patients with multiple myeloma and healthy controls was analyzed by lncRNA chip technology. The serum samples were verified by real-time fluorescence quantitative PCR, and the candidate diagnostic markers were screened out. The ROC working curve was drawn to evaluate the diagnostic efficacy of the candidate markers and to determine their stability at different temperatures and time.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Result&lt;/h3&gt;&lt;p&gt;&lt;span&gt;A total of 44 MM patients and 37 healthy people were involved in this research. Among them, 4 patients with MM and 4 patients with HD were sent for microarray analysis. According to Fold Change ≥ 2 and P &lt; 0.05, a total of 17 differentially expressed lncRNA molecules were screened, of which 9 were up-regulated RNA molecules and 8 were down-regulated RNA molecules. Through real-time fluorescence quantitative PCR verification, it was found that lncRNA CATG00000112921.1 was highly expressed in the healthy control group and diminished &lt;/span&gt;in patients with multiple myeloma, P &lt; 0.001. The ROC curve demonstrated that the area under the curve (AUC) was 0.749, the sensitivity was 0.636, the specificity was 0.789, and the 95 % CI was 0.636-0.862 (P &lt; 0.001). In addition, in order to verify the effects of temperature, time and repeated freezing and thawing on lncRNA, it was placed at 25°C, 4°C, -20°C, -80°C for 0 h, 24 h, 48 h, 72 h, and placed at-80°C repeated freezing and thawing 0 times, 2 times, 4 times, 8 times, and the expression level was not significantly changed.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Serum lncRNA CATG00000112921.1 may be a potential candidate diagnostic marker for multiple myeloma. The ROC curve shows that it has good diagnostic value, and its high stability at different temperatures and different times is a required condition for becoming a diagnostic marker. As far as we know, this is the first study in the world to find differential expression of lncRNA CATG00000112921.1 in peripheral serum of healthy people and newly diagnosed multiple myeloma patients. This ","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"48 ","pages":"Article 101057"},"PeriodicalIF":2.6,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138557432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0147-0272(23)00098-3","DOIUrl":"https://doi.org/10.1016/S0147-0272(23)00098-3","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"47 6","pages":"Article 101045"},"PeriodicalIF":2.6,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138356235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S0147-0272(23)00103-4","DOIUrl":"https://doi.org/10.1016/S0147-0272(23)00103-4","url":null,"abstract":"","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"47 6","pages":"Article 101050"},"PeriodicalIF":2.6,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138356236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemoradiotherapy treatment with gemcitabine improves renal function in locally advanced cervical cancer patients with renal dysfunction","authors":"Silvia Alarcón-Barrios ,&nbsp;Julissa Luvián-Morales ,&nbsp;Denisse Castro-Eguiluz ,&nbsp;Merari Delgadillo-González ,&nbsp;Brenda Olivia Lezcano-Velázquez ,&nbsp;Eder Alexandro Arango-Bravo ,&nbsp;Laura Flores-Cisneros ,&nbsp;Sebastián Aguiar Rosas ,&nbsp;Lucely Cetina-Pérez","doi":"10.1016/j.currproblcancer.2023.101041","DOIUrl":"10.1016/j.currproblcancer.2023.101041","url":null,"abstract":"<div><h3>Background</h3><p><span><span><span>Cervical cancer (CC) in Mexico is diagnosed mainly in locally advanced (LACC) and advanced (ACC) stages, where ureteral obstruction is more frequent. The standard </span>treatment for this population is concurrent </span>chemoradiotherapy (CCRT) with </span>cisplatin<span>, which is nephrotoxic and could lead to further deterioration of renal function in LACC patients with renal function decline. We aimed to evaluate the effect of CCRT with Gemcitabine on renal function in LACC patients.</span></p></div><div><h3>Methods</h3><p>This retrospective study included LACC patients treated with CCRT with Gemcitabine as a radiosensitizer from February 2003 to December 2018. Data were collected from medical archives and electronic records. We assessed renal function before and after CCRT treatment and analyzed the patient's response to treatment and survival.</p></div><div><h3>Results</h3><p><span>351 LACC patients treated were included and stratified into two groups: 198 with Glomerular Filtration Rate (GFR) ≥60ml/min (group A) and 153 with GFR&lt;60ml/min (group B). An improvement in GFR was observed after CCRT </span>in patients<span> in group B, from 33 ml/min to 57.5 ml/min (p&lt;0.001). Complete response was observed in 64.1% of patients in Group A and 43.8% in Group B (p&lt;0.0001). Factors associated with increased risk of death included having a GFR of 15-29 ml/min (HR: 2.17; 1.08-4.35), having GFR&lt;15 ml/min (HR: 3.08; 1.63-5.79), and receiving Boost treatment (HR: 2.09; 1.18-3.69). On the other hand, receiving brachytherapy is a positive predictor for OS (HR:0.51; 0.31-0.84).</span></p></div><div><h3>Conclusion</h3><p>CCRT with gemcitabine is an appropriate treatment option for patients diagnosed with LACC who present impaired renal function due to the disease's obstructive nature or other comorbidities.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"48 ","pages":"Article 101041"},"PeriodicalIF":2.6,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138292391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of nutritional indices and inflammatory parameters on patients received immunotherapy for non-small cell lung cancer","authors":"Hui-Ping Ding ,&nbsp;Yi-Qun Ling ,&nbsp;Wei Chen ,&nbsp;Qin Ding ,&nbsp;Liu-Qing Xu ,&nbsp;Yan Wu ,&nbsp;Qiong Wang ,&nbsp;Tian-Hao Ni ,&nbsp;Bing-Qin He","doi":"10.1016/j.currproblcancer.2023.101035","DOIUrl":"10.1016/j.currproblcancer.2023.101035","url":null,"abstract":"<div><h3>Objective</h3><p><span>This research explored the relationship between a patient's nutritional state and inflammatory markers and the prognosis of their non-small cell lung cancer (NSCLC) treatment while receiving a combination of chemotherapy and </span>immunotherapy.</p></div><div><h3>Method</h3><p><span>This retrospective and single-center analysis included NSCLC patients who received a combination of chemotherapy and immunotherapy at the Department of Oncology at Shanghai Lung Hospital. Patients were categorized based on malnutrition, </span>sarcopenia<span><span>, sarcopenic obesity, and advanced-lung-cancer-inflammation-index (ALI) scores after collecting nutritional and inflammatory indices. Kaplan-Meier and the </span>Cox models were utilized to analyze survival.</span></p></div><div><h3>Results</h3><p>There was a significant correlation between malnutrition, sarcopenia, sarcopenic obesity, and low ALI scores with lower overall survival (OS) and progression-free survival (PFS) (p &lt; 0.05). Low ALI score and malnutrition were independent factors influencing patient survival in terms of both OS and PFS (p &lt; 0.01).</p></div><div><h3>Conclusion</h3><p>The nutritional and inflammatory indices of immunotherapy-treated NSCLC patients substantially affect their prognosis. Assessing these variables could aid in optimizing treatment strategies and improving patient outcomes. Additional research is required to comprehend the intricate relationship between nutrition, inflammation, and cancer progression and to develop individualized therapies.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"48 ","pages":"Article 101035"},"PeriodicalIF":2.6,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138292392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using machine learning algorithms to predict the prognosis of advanced nasopharyngeal carcinoma after intensity-modulated radiotherapy","authors":"Dan Hu ,&nbsp;Ying Wang ,&nbsp;Genxin Ji ,&nbsp;Yu Liu","doi":"10.1016/j.currproblcancer.2023.101040","DOIUrl":"https://doi.org/10.1016/j.currproblcancer.2023.101040","url":null,"abstract":"<div><h3>Background</h3><p><span>The prognosis of advanced nasopharyngeal carcinoma (NPC) patients after intensity-modulated radiotherapy (IMRT) has not been well studied. We aimed to construct prognostic models for advanced NPC patients with stage III-IV after their first </span>treatment with IMRT by using machine learning algorithms and to identify the most important predictors.</p></div><div><h3>Methods</h3><p>A total of 427 patients treated in MeiZhou City People's Hospital in Guangzhou province, China from January 1, 2013 to December 12, 2018 were enrolled in this study, with an average follow-up period of 7.16 years from July 2020 to March 2021. Candidate predictors were selected from demographics, clinical features, medical examinations and test results. Three machine learning algorithms were applied to construct advanced NPC prognostic models: logistic regression (LR), decision tree (DT), and random forest (RF). Area under the receiver operating characteristic curve (AUC) was used to evaluate the model performance. The important predictors of the optimal model for unfavourable prognosis were identified and ranked.</p></div><div><h3>Results</h3><p>There were 50 (11.7%) NPC-related deaths observed in this study. The mean age of all participants was 49.39±11.29 years, of whom 299 (70.0%) were males. In general, RF showed the best predictive performance with the highest AUC (0.753, 95% CI: 0.609, 0.896), compared to LR (0.736, 95% confidence interval (CI): 0.590, 0.881), and DT (0.720, 95% CI: 0.520, 0.921). The six most important predictors identified by RF were Epstein-Barr virus deoxyribonucleic acid, aspartate aminotransferase, body mass index<span><span>, age, blood glucose level, and </span>alanine aminotransferase.</span></p></div><div><h3>Conclusions</h3><p>We proposed RF as a simple and accurate tool for the evaluation of the prognosis of advanced NPC patients after the treatment with IMRT in clinical settings.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"48 ","pages":"Article 101040"},"PeriodicalIF":2.6,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134688929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters","authors":"Leena Gupta ,&nbsp;Pratibha Suku ,&nbsp;Aishwarya Dash ,&nbsp;Parveen Bose ,&nbsp;Praveen Sharma ,&nbsp;Nabhajit Mallik ,&nbsp;Sreejesh Sreedharanunni ,&nbsp;Neelam Varma ,&nbsp;Aditya Jandial ,&nbsp;Pankaj Malhotra ,&nbsp;Man Updesh Singh Sachdeva","doi":"10.1016/j.currproblcancer.2023.101025","DOIUrl":"10.1016/j.currproblcancer.2023.101025","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;p&gt;Circulating plasma cells (CPCs) are frequently noted in variable frequencies in the entire spectrum of plasma cells neoplasms. With advent of high sensitivity multi-parametric flow cytometry, it is not only possible to detect CPCs present in very low numbers, but also to categorise them into circulating tumor plasma cells (CTPCs) and circulating normal plasma cells (CNPCs), based on their marker-profile. This study used multi-colour flow cytometry to evaluate the load of both CTPCs &amp; CNPCs at the time of diagnosis and at six months’ time-point of therapy, and evaluated associations of both with clinical and laboratory parameters.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;Twenty one newly diagnosed MM patients were enrolled. Six to nine millilitres of EDTA-anticoagulated peripheral blood sample was used for flow cytometry. A ten colour antibody panel was used for analysis of CPCs, which were categorised further into CTPCs and CNPCs. Approximately 4.8 million events were acquired for the analysis. The percentage &amp;absolute numbers of CTPCs and CNPCs were noted and the proportion of CTPCs out of all CPCs (CTPCs + CNPCs) were also calculated for evaluating their statistical associations.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;All 21 patients of newly diagnosed MM showed presence of CPCs (CTPCs and/or CNPCs) at the time of diagnosis. The CTPCs were detected in 76 % of the study population. The median percentage and absolute counts of CTPCs were 0.52 % and 54.9 cells /µL, respectively. CNPCs were found in 95 % and the median percentage and absolute counts of CNPCs were 0.025 % and 2.66 cells/µL. After six months of therapy, CPCs (CTPCs and/or CNPCs) were found in all nine patients evaluated for this assay. CTPCs were found 33 %, with a median of 0.075 % and CNPCs were found in 89 % with a median of 0.01 %. Our study showed that the load of CTPCs was found to be higher in patients with presence of lytic bone lesions, plasmacytoma, presence of PCs on peripheral blood film by light microscopy, presence of Chr 1p32 deletion, expression of CD56 and CD81 on CTPCs, and in patients with absence of very good partial response (VGPR). Conversely, the load of CTPCs was significantly lower in patients with concomitant amyloidosis. Also, percentage of bone marrow plasma cells exhibited a significant positive correlation with the absolute count of CTPCs. We observed that the mean percentage of CNPCs was significantly higher in female patients. The load of CNPCs was lower in patients with thrombocytopenia and with hypoalbuminemia.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Increased burden of CTPCs was associated with presence of lytic lesions, plasmacytomas, Chr 1p32 deletion, expression of CD56 and CD81 on tumor cells and with failure to achieve very good partial response. The CNPCs were lower in patients with thrombocytopenia and with hypoalbuminemia. To best ot our knowledge, this is the first study from India on the relevance of circulating tumor pl","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"48 ","pages":"Article 101025"},"PeriodicalIF":2.6,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89720699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}